UK markets closed

RegeneRx Biopharmaceuticals, Inc. (RGRX)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.00140.0000 (0.00%)
As of 01:15PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.10k
Enterprise value 1.40M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.03
Price/book (mrq)N/A
Enterprise value/revenue 18.17
Enterprise value/EBITDA -1.02

Trading information

Stock price history

Beta (5Y monthly) 2.62
52-week change 3-99.98%
S&P500 52-week change 322.38%
52-week high 38.8000
52-week low 30.0002
50-day moving average 30.0064
200-day moving average 30.5769

Share statistics

Avg vol (3-month) 397
Avg vol (10-day) 310
Shares outstanding 51.5M
Implied shares outstanding 61.5M
Float 8806.79k
% held by insiders 144.14%
% held by institutions 10.00%
Shares short (30 Nov 2010) 4191
Short ratio (30 Nov 2010) 40.16
Short % of float (30 Nov 2010) 40.05%
Short % of shares outstanding (30 Nov 2010) 40.03%
Shares short (prior month 29 Oct 2010) 4293

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:100
Last split date 318 Oct 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)31 Mar 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,588.91%

Management effectiveness

Return on assets (ttm)-148.50%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)76.76k
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)-0.00%
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-1.69M
Diluted EPS (ttm)-0.9700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)101.56k
Total cash per share (mrq)0.07
Total debt (mrq)1.49M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.07
Book value per share (mrq)-2.61

Cash flow statement

Operating cash flow (ttm)-823.75k
Levered free cash flow (ttm)-355.28k